文献速递间质性肺疾病

重组人五聚素2蛋白长期治疗特发性肺纤维化:开放标签扩展研究

Long-term treatment with recombinant human pentraxin 2 protein in patients with idiopathic pulmonary fibrosis: an open-label extension study.
PubMed 文献 · Lancet Respir Med · 2019-05-20

本研究为PRM-151-202试验的开放标签扩展研究,111例特发性肺纤维化患者接受PRM-151长期治疗至76周。结果显示PRM-151耐受性良好,不良事件与IPF长期后遗症一致;

要点

  • PRM-151长期治疗耐受性良好,不良事件与IPF长期后遗症一致。

核心结论

  • PRM-151长期治疗耐受性良好,对FVC占预计值百分比和6分钟步行距离的效应在持续治疗中保持,在安慰剂交叉患者中也呈正向效果。

研究设计与样本

  • 开放标签扩展研究,纳入完成28周双盲期的116例患者中的111例(PRM-151组74例,安慰剂组37例)。
  • 所有患者接受PRM-151每28周一个周期,负荷剂量10 mg/kg静脉输注60分钟(第1、3、5天),随后每4周输注10 mg/kg。
  • 主要目标为评估长期安全性和耐受性,分析至第76周所有至少接受一剂PRM-151患者的不良事件。

主要发现

  • 111例中84例(76%)接受合并IPF治疗(吡非尼酮55例,尼达尼布29例)。
  • 31例(28%)发生严重不良事件,常见为肺炎6例(5%)、IPF急性加重4例(4%)、IPF进展4例(4%)、胸痛2例(2%)。
  • 21例(19%)发生严重不良事件,IPF急性加重和IPF进展各2例(2%);2例(2%)发生危及生命的不良事件(肺炎1例,广泛期小细胞肺癌1例)。

临床怎么用

  • PRM-151长期治疗耐受性良好,对FVC和6分钟步行距离的效应持续,支持在更大IPF人群中进一步研究。

局限性

  • 为开放标签扩展研究,无安慰剂对照,探索性疗效分析需谨慎解读。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Patients with idiopathic pulmonary fibrosis (IPF) treated with PRM-151, a recombinant human pentraxin 2 protein, in a phase 2 double-blind, randomised controlled trial had significantly reduced decline in percentage of predicted forced vital capacity (FVC) and stabilised 6-min walking distance compared with placebo over a 28-week period. Here we report the 76-week results of an open-label extension study. METHODS: Patients who completed the 28-week double-blind period of the PRM-151-202 trial were eligible to participate in the open-label extension study. Patients previously enrolled in the PRM-151 group continued this treatment and those previously in the placebo group crossed over to PRM-151. All patients received PRM-151 in 28-week cycles with loading doses of 10 mg/kg by 60 min intravenous infusions on days 1, 3, and 5 in the first week of each cycle followed by one infusion of 10 mg/kg every 4 weeks. The primary objective of the open-label extension study was to assess the long-term safety and tolerability of PRM-151, which were assessed by analysing adverse events (AEs) up to week 76 in all patients who received at least one dose of PRM-151 during the open-label extension study. Exploratory efficacy analyses were done by assessing changes from baseline in percentage of predicted FVC and 6-min walking distance, with descriptive statistics to week 76 and with random-intercept mixed models to week 52. This study is registered with ClinicalTrials.gov, number NCT02550873, and with EudraCT, number 2014-004782-24. FINDINGS: Of 116 patients who completed the double-blind treatment period, 111 entered the open-label extension study (74 from the PRM-151 group and 37 from the placebo group). 84 (76%) of 111 patients received concomitant IPF therapy (pirfenidone n=55 or nintedanib n=29). AEs were consistent with long-term IPF sequelae. 31 (28%) patients had serious AEs. Those occurring in two or more patients were pneumonia (six [5%] of 111), IPF exacerbation (four [4%]), IPF progression (four [4%]), and chest pain (two [2%]). 21 (19%) patients had severe AEs, of which IPF exacerbation and IPF progression each occurred in two (2%) patients. Two (2%) patients experienced life-threatening AEs (one had pneumonia and one had small-cell lung cancer extensive stage). A persistent treatment effect was observed for PRM-151 in patients who continued treatment, with a decline in percentage of predicted FVC of -3·6% per year and in 6-min walking distance of -10·5 m per year at week 52. In patients who started PRM-151 during the open-label extension study, compared with the slopes for placebo, decline reduced for percentage of predicted FVC (from -8·7% per year in weeks 0-28 to -0·9% per year in weeks 28-52, p<0·0001) and 6-min walking distance (from -54·9 m per year to -3·5 m per year, p=0·0224). INTERPRETATION: Long-term treatment with PRM-151 was well tolerated and the effects on percentage of predicted FVC and 6-min walking distance were persistent on continuation and positive in patients who crossed over from placebo. These findings support further study of PRM-151 in larger populations of patients with IPF. FUNDING: Promedior.

来源:Lancet Respir Med,查看原文。版权归原作者所有。

引用

  1. Raghu G, van den Blink B, Hamblin MJ, et al. Long-term treatment with recombinant human pentraxin 2 protein in patients with idiopathic pulmonary fibrosis: an open-label extension study. Lancet Respir Med. 2019. PMID: 31122893. doi:10.1016/S2213-2600(19)30172-9

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。